BELLEVILLE, ON, Aug. 23 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company, today
announced that the first permit has been issued for its E. coli O157:H7 cattle
vaccine ("the vaccine"), and that the first order of vaccine has been shipped
to that customer.
The vaccine will be used for the reduction of shedding of E. coli O157:H7
bacteria in cattle. Shed bacteria can contaminate food, water and the
environment. Human exposures to this pathogen result in an estimated 100,000
cases of illness per year in North America. Bioniche believes that use of the
vaccine will reduce the amounts of bacteria in cattle and the related
incidence of human disease.
The vaccine remains under review by The Canadian Food Inspection Agency
(CFIA) and The United States Department of Agriculture (USDA). In the course
of its review process, the CFIA notified Bioniche last December that it was
agreeable to issuing permits under the Permit to Release Veterinary Biologics
regulations. These regulations allow cattle owners, through their
veterinarians, to request vaccine be supplied to them by Bioniche. At the time
this arrangement was accorded to the Company, meaningful quantities of vaccine
were not yet available.
Since that time, Bioniche has commenced production of the E. coli O157:H7
cattle vaccine at its Belleville, Ontario facility. This supply is now being
provided to veterinarians requesting vaccine under the Canadian Permit to
Release regulations. Bioniche will continue to scale up as full domestic and
international approvals are received. Until such approvals are received, all
vaccine will be shipped to Canadian veterinarians as permit requests are
received and approved by the CFIA.
In order to progress from shipping under permits to a full license, the
CFIA indicated that Bioniche was required to provide additional data
confirming reduction in E. coli O157:H7 shedding by vaccinated animals. This
information was provided to the CFIA in the spring and is currently under
Further information about initial vaccine orders will follow as such
customers consent to its disclosure and as Bioniche reports its financial
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
185 skilled personnel and has three operating divisions: Human Health, Animal
Health, and Food Safety. The Company's primary goal is to develop proprietary
cancer therapies supported by revenues from marketed products in human and
animal health. For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause, but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.
For further information:
For further information: Jennifer Shea, Corporate Communications &
Investor Relations Manager, Bioniche Life Sciences Inc., Telephone: (613)
966-8058, Cell: (613) 391-2097, Jennifer.Shea@Bioniche.com